Sugi Predict

Sugi Predict / Targets / CD58

CD58

Lymphocyte function-associated antigen 3 · P19256 · CD58 on Sugi Atlas →

69 patent compounds predicted against CD58, 60 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL31060461 SCHEMBL31060461 0.56 1/20
SCHEMBL19375812 SCHEMBL19375812 0.54 1/20
SCHEMBL10049951 SCHEMBL10049951 0.54 1/20
SCHEMBL19367902 SCHEMBL19367902 0.53 1/20
SCHEMBL22891909 SCHEMBL22891909 0.53 1/20
SCHEMBL23968131 SCHEMBL23968131 0.53 1/20
SCHEMBL21312758 SCHEMBL21312758 0.53 1/20
SCHEMBL22844368 SCHEMBL22844368 0.53 1/20
SCHEMBL15840391 SCHEMBL15840391 0.52 1/20
SCHEMBL15840412 SCHEMBL15840412 0.52 1/20
SCHEMBL31060963 SCHEMBL31060963 0.52 1/20
SCHEMBL19299795 SCHEMBL19299795 0.51 1/20
SCHEMBL21664077 SCHEMBL21664077 0.50 1/20
SCHEMBL19581485 SCHEMBL19581485 0.49 1/20
SCHEMBL31060302 SCHEMBL31060302 0.49 1/20
SCHEMBL19018674 SCHEMBL19018674 0.48 1/20
SCHEMBL7746029 SCHEMBL7746029 0.48 1/20
SCHEMBL15308347 SCHEMBL15308347 0.48 1/20
SCHEMBL19018807 SCHEMBL19018807 0.48 1/20
SCHEMBL22618578 SCHEMBL22618578 0.48 1/20

Clinical trials — most relevant to CD58 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
co Ihibtory Receptor in Preeclampsia PHASE4UNKNOWN
Sequential CAR-T Cells Therapy for CD5/CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD5/CD7-Specific CAR-T Cells PHASE1/PHASE2RECRUITING
Multi-CAR T Cell Therapy for Acute Myeloid Leukemia PHASE1/PHASE2RECRUITING
CD5 Chimeric Antigen Receptor (CAR) T Cells in Subjects With Relapsed or Refractory T-cell Malignancies PHASE1/PHASE2RECRUITING
CD5 CAR T-Cell Therapy for r/r T-cell Lymphomas PHASE1/PHASE2RECRUITING
Multiple CAR-T Cell Therapy Targeting AML PHASE1/PHASE2RECRUITING
Study of Anti-CD33 Chimeric Antigen Receptor-Expressing T Cells (CD33CART) in Children and Young Adults With Relapsed/Refractory Acute Myeloid Leukemia PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Daratumumab in Combination With ATRA PHASE1/PHASE2COMPLETED
A Multicenter, Open-Label, Non-Randomized, Single-Arm Clinical Study of Nanobody CD5-CAR T Cell Therapy for Refractory/Relapsed T Lymphocyte Malignancies PHASE1/PHASE2RECRUITING
Fludarabine Combined With Either Alemtuzumab or Rituximab in Treating Patients With Refractory or Relapsed B-Cell Chronic Lymphocytic Leukemia PHASE2COMPLETED
CD5 CAR-T Therapy for Refractory/Relapsed CD5+ T-cell Acute Lymphoblastic Leukemia PHASE1UNKNOWN
CHOP and Campath-1H in Previously Untreated Aggressive T/NK-Cell Lymphomas PHASE1COMPLETED
CD5789 in Early Cutaneous T-Cell Lymphoma (CTCL) PHASE1COMPLETED
Treatment of T-Large Granular Lymphocyte (T-LGL) Lymphoproliferative Disorders With Cyclosporine PHASE1COMPLETED
A Study of JNJ-75348780 in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) PHASE1COMPLETED
Targeting CD5 CAR-T Cells in the Treatment of r/r CD5+ T-lymphoma EARLY_PHASE1RECRUITING
Study of Anti-CD33/CLL1 CAR-NK in Acute Myeloid Leukemia EARLY_PHASE1UNKNOWN
Targeting CD5 CAR-T Cells in the Treatment of r/r CD5+ T-ALL EARLY_PHASE1RECRUITING
Alefacept in Patients With Severe Scalp Alopecia Areata nanCOMPLETED
CD5 CART for the Treatment of Relapsed and Refractory CD5 Hematological Tumors nanRECRUITING
Letermovir in ART-treated HIV-infected Persons nanCOMPLETED
Fish Oil for HIV-Related Inflamm-aging and Immune Senescence nanCOMPLETED
Using of Costimulatory and co Inhibatory Immune Checkpoints as Diagnostic and Prognostic in Breast Cancer nanUNKNOWN
Role of CD11a in Pathogenesis of Primary ITP and Effect of Immunosuppressive Therapy on Its Level nanCOMPLETED
Complement Regulatory Proteins Expression and Clinical Response in Rheumatoid Arthritis (RA) Patients Treated With Rituximab nanUNKNOWN
Clinical Study on Safety and Efficacy of Anti-CLL1 /+CD33 CAR T Cells in the Treatment of Acute Myeloid Leukemia nanWITHDRAWN
Precision Physical Exercise for Personalized Onco-Hematology. nanNOT_YET_RECRUITING
Expression of CD19 Complex in Lymphoproliferative Disorders nanUNKNOWN
The Molecular Biology of Paroxysmal Nocturnal Hemoglobinuria (PNH) nanCOMPLETED
LoViReT (Low Viral Reservoir Treated Patients) nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a CD58 binder may also engage these)

ProteinNameSimilarity
P04218 — 0.990 P04218 →
P18181 — 0.987 P18181 →
P42071 — 0.986 P42071 →
P09326 — 0.984 P09326 →
Q8K4F0 — 0.984 Q8K4F0 →
Q2YHT7 — 0.983 Q2YHT7 →
P10252 — 0.983 P10252 →
Q9JLM2 — 0.983 Q9JLM2 →
B0CLX4 — 0.982 B0CLX4 →
Q9D7L8 — 0.982 Q9D7L8 →
P20489 — 0.982 P20489 →
O54901 — 0.982 O54901 →
P42082 — 0.982 P42082 →
A8MVW5 — 0.982 A8MVW5 →
P42081 — 0.981 P42081 →
Q9UM44 — 0.981 Q9UM44 →
Q5RAL8 — 0.981 Q5RAL8 →
Q4VAH7 — 0.981 Q4VAH7 →
Q15762 — 0.981 Q15762 →
Q6GMZ9 — 0.980 Q6GMZ9 →
P0DTU3 — 0.980 P0DTU3 →
Q80UL9 — 0.979 Q80UL9 →
A6QQC6 — 0.979 A6QQC6 →
P20748 — 0.979 P20748 →
Q8AVM3 — 0.979 Q8AVM3 →
P08920 — 0.979 P08920 →
Q3T113 — 0.979 Q3T113 →
CD2 T-cell surface antigen CD2 0.978 landscape →
P35329 — 0.978 P35329 →
Q00609 — 0.978 Q00609 →